Reported about 15 hours ago
UnitedHealth has postponed its earnings report for the second quarter amid increasing medical costs and is now scheduled to announce results on Tuesday. In contrast, Sarepta Therapeutics faces FDA scrutiny over drug-related fatalities, even as its stock experiences unexpected gains following a financial milestone payment. The healthcare sector is under notable pressure, raising concerns about UnitedHealth's revenue expectations and Sarepta's future amid ongoing investigations.
Source: YAHOO